试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-23
Intraarticular Platelet-rich Plasma Injections Versus Corticosteroid Injections in Primary Knee Osteoarthritis
编号:NCT01923909登记状态:入组前撤回企业 / 申办者:King Hamad University Hospital, Bahrain
药物 / 成分:Intra-articular platelet-rich plasma、Intra-articular corticosteroid injections
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-23
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
编号:NCT03527056登记状态:入组前撤回企业 / 申办者:University of California, Los Angeles
药物 / 成分:Fecal Microbiota Transplantation
登记的停止原因(原文):Investigator left the institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-22
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
编号:NCT03996486登记状态:入组前撤回企业 / 申办者:Bayer
药物 / 成分:BAY1093884
登记的停止原因(原文):Company decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-21
Myfortic in High MELD Liver Transplantation
编号:NCT01807767登记状态:入组前撤回企业 / 申办者:Medical College of Wisconsin
药物 / 成分:Everolimus, Myfortic and Tacrolimus、Myfortic and Tacrolimus
登记的停止原因(原文):funding was withdrawn
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-21
T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
编号:NCT03311672登记状态:入组前撤回企业 / 申办者:University of California, San Francisco
药物 / 成分:[18F]F-Ara-G、Pembrolizumab、PET/CT scan
登记的停止原因(原文):Low Accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-18
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
编号:NCT03281681登记状态:入组前撤回企业 / 申办者:DelMar Pharmaceuticals, Inc.
药物 / 成分:VAL-083, Dianhydrogalactitol
登记的停止原因(原文):Alternate study design for ovarian cancer under discussion
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-17
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
编号:NCT02030184登记状态:入组前撤回企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Rhenium Re 188-P2045
登记的停止原因(原文):PI has left the study institution.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-17
The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery
编号:NCT03679481登记状态:入组前撤回企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:Tranexamic acid (TXA)、Normal saline
登记的停止原因(原文):study not started due to lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-17
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
编号:NCT04130399登记状态:入组前撤回企业 / 申办者:Indiana University
药物 / 成分:Stereotactic Body Radiation Therapy (SBRT)、FOLFIRINOX
登记的停止原因(原文):Study is being abandoned.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-10-16
Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children
编号:NCT02656888登记状态:入组前撤回企业 / 申办者:EMS
药物 / 成分:Irlanda-1-Association、Placebo
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗